Influence of a dose-dense adjuvant chemotherapy on sVCAM-1/sICAM-1 serum levels in breast cancer patients with 1-3 positive lymph nodes

Anticancer Research

Volumn 31, Issue 8, 2011, Pages 2617-2622

  Eggeman, Holm ^a   Stöblen, Frank ^b   Thill, Marc ^c   Korlach, Susanne ^h   Schmid, Peter ^d   Lüftner, Diana ^e   Elling, Dirk ^f   Taran, Florin Andrei ^a   Kümmel, Sherko ^b   Landt, Solveig ^g  

^a UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^b KLINIKEN ESSEN MITTE   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d UNIVERSITY OF SUSSEX   (United Kingdom)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f Oskar Ziethen Hospital   (Germany)

^g UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^h NONE

Author keywords

Breast cancer; Chemotherapy; Dose dense; sICAM 1; sVCAM 1

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; INTERCELLULAR ADHESION MOLECULE 1; PACLITAXEL; VASCULAR CELL ADHESION MOLECULE 1;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DOSE REGIMEN; FEMALE; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SERUM;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; LYMPHATIC METASTASIS; MIDDLE AGED; POSTMENOPAUSE; PREMENOPAUSE; VASCULAR CELL ADHESION MOLECULE-1;

EID: 79961175789     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Menger MD and Vollmar B: Adhesion molecules as determinants of disease: from molecular biology to surgical reseach. Br J Surg 83: 588-601, 1996. (Pubitemid 26163543)
2. Gutman M and Fidler IJ: Biology of human colon cancer metastasis. World J Surg 19: 226-234, 1995.
3. Zetter BR: Adhesion molecules in tumor metastasis. Sem Cancer Biol 4: 219-229, 1993.
4. Frenette PS and Wagner DD: Adhesion molecules-part I. N Engl J Med 334: 1526-1529, 1996.
5. Frenette PS and Wagner DD: Adhesion molecules-part II. N Engl J Med 335: 43-45, 1996.
6. Meyer T and Hart IR: Mechanisms of tumor metastasis. Eur J Cancer 34: 214-221, 1998.
7. Gearing AJ, Hemingway I, Pigott R, Hughes J, Rees AJ and Cashman SJ: Souble forms of vascular adhesion molecules, E-selectin, ICAM-1 and VCAM-1: pathological significance. Ann N Y Acad Sci 667: 324-331, 1992. (Pubitemid 23061599)
8. Gearing AJ and Newman W: Circulating adhesion molecules in disease. Immunol Today 14: 506-512, 1993.
9. Banks RE, Gearing AJ, Hemingway IK, Norfolk DR, Perren TJ and Selby PJ: Circulating intercellular adhesion molecule-1 (ICAM-1), E-selectin and vascular cell adhesion molecule-1 (VCAM-1) in human malignancies. Br J Cancer 68: 122-124, 1993. (Pubitemid 23178563)
10. Hakomori S: Novel endothelial cell activation factors released from platelets which induce E-selectin expression and tumor cell adhesion to endothelial cells: a preliminary note. Biochem Biophys Res Comm 203: 1605-1613, 1994.
11. Velikova G, Banks RE, Gearing A, Hemingway I, Forbes MA, Preston SR, Hall NR, Jones M, Wyatt J, Miller K, Ward U, Al-Maskatti J, Singh SM, Finan PJ, Ambrose NS, Primrose JN and Selby PJ: Serum concentrations of soluble adhesion molecules in patients with colorectal cancer. Br J Cancer 77: 1857-1863, 1998.
12. Nakata B, Hori T, Sunami T, Ogawa Y, Yashiro M, Maeda K, Sawada T, Kato Y, Ishikawa T and Hirakawa K: Clinical significance of serum soluble intercellular adhesion molecule 1 in gastric cancer. Clin Cancer Res 6: 1175-1179, 2000. (Pubitemid 30159382)
13. O'Hanlon DM, Fitzsimons H, Lynch J, Tormey S, Malone C and Given HF: Soluble adhesion molecules (E-selectin, ICAM-1 and VCAM-1) in breast carcinoma. Eur J Cancer 38: 2252-2257, 2002. (Pubitemid 35346466)
14. Zhang GJ and Adachi I: Serum levels of soluble intercellular adhesion molecule-1 and E-selectin in metastatic breast carcinoma: correlations with clinicopathological features and prognosis. Int J Oncol 14: 71-77, 1999.
15. Mills PJ, Parker B, Jones V, Adler KA, Perez CJ, Johnson S, Cohen-Zion M, Marier M, Sadler GR, Dimsdale JE and Ancoli-Israel S: The effects of standard anthracycline-based chemotherapy on soluble ICAM-1 and vascular endothelial growth factor levels in breast cancer. Clin Cancer Res 10: 4998-5003, 2004.
16. Kümmel S, Krocker J, Kohls A, Breitbach GP, Morack G, Budner M, Blohmer JU and Elling D: Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer. Br J Cancer 94: 1237-1244, 2006.
17. Citron ML, Berry DA, Cirrincione C and Hudis C: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21: 1431-1439, 2003. (Pubitemid 46594092)
18. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei E 3rd, Schilsky RL, Wood WC, Muss HB and Norton L: Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21: 976-983, 2003.
19. Klein B, Levin I, Kfir B, Mishaeli M, Shapira J and Klein T: The significance of soluble interleukin-2, soluble interleukin-2 receptors, soluble ICAM-1 and beta 2-microglobulin in breast cancer patients. Tumour Biol 16: 290-296, 1995.
20. Spielmann M, Roché H, Delozier T, Canon JL, Romieu G, Bourgeois H, Extra JM, Serin D, Kerbrat P, Machiels JP, Lortholary A, Orfeuvre H, Campone M, Hardy-Bessard AC, Coudert B, Maerevoet M, Piot G, Kramar A, Martin AL and Penault-Llorca F: Trastuzumab for patients with axillary node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol 27: 6129-6134, 2009.
21. Köstler WJ, Tomek S, Brodowicz T, Budinsky AC, Flamm M, Hejna M, Krainer M, Wiltschke C and Zielinski CC: Soluble ICAM-1 in breast cancer: clinical significance and biological implications. Cancer Immunol Immunother 50: 483-490, 2001. (Pubitemid 33079345)
22. Blann AD, Lip GY and McCollum CN: Changes in von Willebrand factor and soluble ICAM, but not soluble VCAM, soluble E selectin or soluble thrombomodulin, reflect the natural history of the progression of atherosclerosis. Atherosclerosis 165: 389-391, 2002. (Pubitemid 35333367)
23. Tsavaris N, Kosmas C, Vadiaka M, Kanelopoulos P and Boulamatsis D: Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer 87: 21-27, 2002.
24. Setti M, Bignardi D, Ballestrero A, Ferrando F, Musselli C, Blanchi S, Basso M, Bosco O, Balleari E, Patrone F and Indiveri F: The induction of distinct cytokine cascades correlates with different effects of granulocyte colony-stimulating factor and granulocyte/macrophage colony-stimulating factor on the lymphocyte compartment in the course of high-dose chemotherapy for breast cancer. Cancer Immunol Immunother 48: 287-296, 1999. (Pubitemid 29434188)
25. Merendino RA, Gangemi S, Ruello A, Bene A, Losi E, Lonbardo G and Purello-Dambrosio F: Serum levels of interleukin-18 and sICAM-1 in patients affected by breast cancer: preliminary considerations. Int J Biol Markers 16: 126-129, 2001.
26. Hutchins D and Steel CM: Regulation of ICAM-1 (CD54) expression in human breast cancer cell lines by interleukin 6 and fibroblast-derived factors. Int J Cancer 58: 80-84, 1994. (Pubitemid 24213973)